BioPharmSignal logoBioPharmSignal

Biotech News

Liquidia Corporation Announces Preliminary Full-Year 2025 YUTREPIA Net Sales and Corporate Update

Liquidia Corporation (LQDA)Liquidia CorporationEarnings

Estimated YUTREPIA™ net product sales of approximately $90.1 million in the fourth quarter and $148.3 million for full-year 2025 Received more than 2,800 unique patient prescriptions since launch in June 2025 Generated more than $30 million of positive cash flow during the fourth quarter 2025

Related news

LQDALiquidia Corporation2025-11-03 11:30 EST

Liquidia Corporation Reports Third Quarter 2025 Financial Results and Provides Corporate Update

LQDALiquidia Corporation2026-03-05 11:30 EST

Liquidia Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

View all latest news

Liquidia Corporation

Pulmonary Hypertension Company Liquidia develops and commercializes therapies for pulmonary hypertension. Its product strategy applies particle-engineering technology to improve delivery of established medicines. YUTREPIA YUTREPIA is a dry-powder formulation of treprostinil delivered through a compact, low-effort inhaler. It is approved...

Recent company news

LQDALiquidia Corporation2026-08-12 10:30 EST

Liquidia Corporation Reports Second Quarter 2026 Financial Results

LQDALiquidia Corporation2026-07-29 12:30 EST

Liquidia Corporation to Report Second Quarter 2026 Financial Results on August 12, 2026

LQDALiquidia Corporation2026-06-11 12:30 EST

Liquidia Announces Poster Presentations at the PHA 2026 International PH Conference and Scientific Sessions

LQDALiquidia Corporation2026-06-08 12:30 EST

Liquidia Corporation Announces Inclusion in the S&P SmallCap 600® Index

LQDALiquidia Corporation2026-05-27 12:30 EST

Liquidia Corporation to Present at 2026 Jefferies Global Healthcare Conference

Stock data

Close
68.62 USD
Market cap
4.9B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States